Results For "Moberg"

2 News Found

Moberg Pharma reports 2025 annual results, maintains strong cash position amid continued investments

News | April 17, 2026

Moberg Pharma reports 2025 annual results, maintains strong cash position amid continued investments

The company reported net revenue of SEK 13.5 million for the full year 2025

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Clinical Trials | October 09, 2023

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Latest Stories

Danone India backs community-led anaemia screening for 1 lakh children in UP

Salve Group launches Parasoft foot cream to address dry and cracked feet

Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging